Olfr605, a member of the olfactory receptor family, holds a pivotal role in orchestrating olfactory signal transduction within the sensory epithelium. As a G protein-coupled receptor (GPCR), Olfr605 contributes to the detection and transduction of specific odorant molecules, initiating a cascade of events that culminate in the perception of olfactory stimuli. Functionally, Olfr605 activates adenylate cyclase, leading to an elevation in cyclic AMP (cAMP) levels. This, in turn, sets off downstream signaling pathways associated with olfactory signal transduction. The intricate mechanism of Olfr605 involves its participation in the cyclic AMP signaling pathway, a crucial component of olfactory signal transduction. Upon activation by specific odorants, Olfr605 stimulates adenylate cyclase, triggering the production of cAMP. Elevated cAMP levels orchestrate a series of events that ultimately lead to the perception of the corresponding odorant. The specificity of Olfr605 in recognizing distinct odorants highlights its role as a molecular mediator in the complex process of olfactory perception.
Inhibition of Olfr605 involves a spectrum of chemicals that target key cellular pathways associated with its function. Indirect inhibitors, such as those modulating the Ras/MAPK pathway or influencing calcium signaling, disrupt the intricate network of signaling cascades that facilitate Olfr605 activation. These compounds interfere with upstream events, negatively regulating Olfr605 expression and function. Additionally, direct inhibitors that specifically target kinases, like protein kinase C (PKC) or mitogen-activated protein kinase (MAPK), directly suppress Olfr605 activity by disrupting downstream signaling events. The diverse mechanisms of inhibition shed light on the complex regulatory network governing Olfr605 function, providing valuable insights into potential strategies for modulating olfactory signal transduction. The interplay between these inhibitors and the intricate pathways associated with Olfr605 underscores the multifaceted nature of olfactory receptor regulation and opens avenues for further exploration into the molecular intricacies of olfactory perception.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
2-Nitroso-1-naphthol | 132-53-6 | sc-238180 | 10 g | $47.00 | ||
2-Nitroso-1-naphthol inhibits Olfr605 by disrupting the cAMP signaling pathway. It specifically targets adenylate cyclase, reducing cAMP levels and downstream activation of Olfr605. | ||||||
Dibenzoylmethane | 120-46-7 | sc-204719 sc-204719A | 25 g 100 g | $37.00 $51.00 | ||
Dibenzoylmethane serves as an indirect inhibitor by modulating the Ras/MAPK pathway. Its interference with Ras activation leads to downstream effects that negatively regulate Olfr605 expression. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin inhibits Olfr605 through calcium signaling modulation. Elevated intracellular calcium disrupts downstream cascades, affecting Olfr605 function and reducing its cellular impact. | ||||||
Trifluoperazine Dihydrochloride | 440-17-5 | sc-201498 sc-201498A | 1 g 5 g | $56.00 $99.00 | 9 | |
Trifluoperazine acts as an indirect inhibitor by perturbing the GPCR signaling network. Its influence on G proteins disrupts intracellular signaling pathways, resulting in the inhibition of Olfr605. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Phorbol 12-myristate functions as a direct inhibitor, targeting protein kinase C (PKC). Inhibition of PKC alters downstream events, negatively impacting Olfr605 activity within the cellular context. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin acts on the PI3K/Akt pathway, indirectly inhibiting Olfr605. By disrupting Akt activation, it interferes with the downstream signaling cascades essential for Olfr605 function. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $27.00 $52.00 | 37 | |
2-APB hinders Olfr605 by affecting the cGMP signaling pathway. It specifically targets guanylate cyclase, leading to reduced cGMP levels and subsequent inhibition of Olfr605. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 serves as an indirect inhibitor by targeting PI3K. Its interference with PI3K disrupts downstream Akt signaling, negatively impacting Olfr605 function within the cellular environment. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits Olfr605 through disruption of the endoplasmic reticulum calcium stores. The altered calcium homeostasis negatively affects Olfr605 signaling and overall cellular impact. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine acts as a direct inhibitor by targeting protein kinase C. Its inhibitory effect on PKC disrupts downstream signaling, leading to the suppression of Olfr605 within cellular contexts. |